Peptide Association

Insights

NewsBlog
Start free intake

DisclosurePeptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.

All peptides

Hormone · FDA Approved

Tesamorelin (Egrifta)

FDA-approved

Start your consultation
Written by Peptide Association Editorial TeamLast reviewed Editorial policy

01 · Overview

A synthetic GHRH analog consisting of the full 44-amino acid sequence of human GHRH with a trans-3-hexenoic acid modification at the N-terminus to improve stability. By stimulating the body's own GH secretion, tesamorelin reduces excess visceral (abdominal) fat in people with HIV while generally maintaining glucose control, though the fat returns when treatment stops (PMID 21695284).

It is FDA-approved for reducing excess abdominal fat in HIV-infected patients with lipodystrophy.

02 · Research summary & key findings

FDA-approved in 2010 for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. In pooled phase 3 trials, visceral adipose tissue fell by a placebo-adjusted 15.4% at 26 weeks, with improvements in triglycerides, without significant change in subcutaneous fat (PMID 20554713). In a randomized trial in people with HIV and NAFLD, tesamorelin reduced liver fat by 37% relative to baseline versus placebo (PMID 31611038).

03 · Regulatory status

Tesamorelin (Egrifta) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.

04 · Administration routes

  • Subcutaneous injection (daily)

References

  1. [1]Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data J Clin Endocrinol Metab, 2010. PMID 20554713
  2. [2]Tesamorelin: a novel therapeutic option for HIV/HAART-associated increased visceral adipose tissue Drugs Today (Barc), 2011. PMID 21695284
  3. [3]Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial Lancet HIV, 2019. PMID 31611038

Primary literature

Related peptides in Hormone

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.